
Please try another search
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Rohan Palekar | 59 | 2018 | CEO & Director |
Derek Paul DiRocco | 44 | 2018 | Independent Director |
Steven M. Altschuler Buser | 72 | 2020 | Independent Chairman of the Board |
Michael R. Hayden | 74 | 2018 | Independent Director |
Kathleen D. LaPorte | 63 | 2021 | Independent Director |
Edward Morrow Atkinson | 58 | 2022 | Independent Director |
Martin Babler | 60 | 2024 | Independent Director |
Lota S. Zoth | 65 | 2020 | Independent Director |
Charles A. McWherter | 70 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review